CLINICAL RESEARCH

Our Clinical Research Division

Dr. Corren has been involved in clinical research in the fields of allergy, asthma and immunology for over 25 years and has participated in pioneering studies of new biologic medications, unique forms of allergen immunotherapy, and new formulations of IVIG for patients with severe asthma, nasal polyps, atopic dermatitis, hives, severe nasal allergies, and immune deficiency. Please visit the following links to learn more about a few of Dr. Corren’s recent publications:   

To visit our Research Division Facebook page, click here

Why Participate In Clinical Research?

Many patients have allergic and immune disorders which are not well-controlled with existing treatments.  Our practice works with the National Institute of Health and many pharmaceutical companies to help develop medications that are safer and more effective than current therapies.  By participating in a clinical trial, you may help your own condition, and just as importantly, will contribute significantly to improved health and well-being for millions of patients throughout the world who suffer from asthma, severe nasal and sinus disease, allergic skin disorders, and immune deficiency.

Current Research Studies

Tezepelumab for severe asthma

Tezepelumab is a new medication for severe, uncontrolled asthma and has been shown to be effective in patients who have not responded to other therapies.  The current research study is recruiting patients who are currently using a controller therapy (such as Advair, BreoEllypta, Symbicort) and are still having symptoms of asthma. You will receive the medication free of charge and will be paid for your time and travel.  

Clinical Research Coordinator: Claudia

310-477-1734 ext. 3

 

Fevipiprant for uncontrolled asthma

Fevipiprant is a new oral medication for patients who have not responded to other therapies.  The current research study is recruiting patients who are currently using a controller therapy (such as Qvar, Pulmicort, Advair, BreoEllypta, Symbicort) and are still having symptoms of asthma.  You will receive the medication free of charge and will be paid for your time and travel.

Clinical Research Coordinator: Claudia

310-477-1734 ext. 3

Benralizumab for severe, oral steroid-dependent asthma

Benralizumab (Fasenra) is an FDA-approved medication for patients with severe asthma.  The current research study is recruiting patients who need to take prednisone at a dose of at least 5 mg per day.  You will receive the medication free of charge and will be paid for your time and travel.

 

Clinical Research Coordinator: Angelica

310-477-1734 ext. 2

Roche ST2 inhibitor for severe atopic dermatitis

Roche ST2 inhibitor is a new medication in development for patients with moderate-severe atopic dermatitis, also known as allergic eczema.  The current research study is recruiting patients who have not responded well to previous therapies. You will receive the medication free of charge and will be paid for your time and travel.  

 

Clinical Research Coordinator: Angelica

310-477-1734 ext. 2

 

XHance for chronic sinusitis

XHance is a new type of nasal spray which has been shown to be very effective in patients with nasal polyps.  The current research study is recruiting patients who have chronic sinus problems. You will receive the medication free of charge and will be paid for your time and travel.  

 

Clinical Research Coordinator: Angelica

310-477-1734 ext. 2

 

Dupilumab for eosinophilic esophagitis

Dupilumab is an FDA-approved medication for severe asthma and atopic dermatitis and is now being evaluated for patients with eosinophilic esophagitis.  The current research study is recruiting patients who have been diagnosed with eosinophilic esophagitis by endoscopy. You will receive the medication free of charge and will be paid for your time and travel.  

 

Clinical Research Coordinator: Claudia

310-477-1734 ext. 3

Jonathan Corren M.D. and Associates

10780 Santa Monica Boulevard

Suite 280

Los Angeles, CA 90025

Tel: 310-312-5050

Fax: 310-575-9292

Research: 310-477-1734

Email: info@correnmd.com

  • Facebook Social Icon